ReviewBiomolecules2021
Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Chemical Composition and Preliminary Screening of Anticholinesterase and Antioxidant Activities of the Essential Oil ofPlants (Basel, Switzerland) · 2026Article
- Effect of Chemical Profile on In Vitro Biological Activities of Essential Oils from Southeast MoroccanInternational journal of molecular sciences · 2026Article
- Germacrone Ameliorates Diabetic Kidney Disease by Activating TFEB to Promote Autophagy and Inhibit Inflammation.ACS omega · 2025Article
- Chemical Constituents, In Silico Studies and In Vitro Antioxidant, Enzyme Inhibitory and Antibacterial Activities of the AlgerianPlants (Basel, Switzerland) · 2025Article
- Role of Phytonutrients in the Prevention and Treatment of Chronic Diseases: A Concrete Review.ACS omega · 2025Review
- Promising Natural Remedies for Alzheimer's Disease Therapy.Molecules (Basel, Switzerland) · 2025Review
- Phytochemical Investigation ofPlants (Basel, Switzerland) · 2025Article
- Mechanism of Action and Therapeutic Potential of Xanthohumol in Prevention of Selected Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Umbelliprenin attenuates comorbid behavioral disorders in acetic acid-induced colitis in mice: mechanistic insights into hippocampal oxidative stress and neuroinflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- GC-MS-based metabolic profiling of essential oils fromFrontiers in chemistry · 2025Article
- Insulin Resistance Is a Modifying Factor for Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Article
- Emodin derivatives as promising multi-aspect intervention agents for amyloid aggregation: molecular docking/dynamics simulation, bioactivities evaluation, and cytoprotection.Molecular diversity · 2024Article
- Design of Promising Thiazoloindazole-Based Acetylcholinesterase Inhibitors Guided by Molecular Docking and Experimental Insights.ACS chemical neuroscience · 2024Article
- Neuropsychopharmacological Induction of (Lucid) Dreams: A Narrative Review.Brain sciences · 2024Review
- The impact of seasonal variation on the composition of the volatile oil of Polyalthia suberosa (Roxb.) Thwaites leaves and evaluation of its acetylcholinesterase inhibitory activity.BMC complementary medicine and therapies · 2024Article
- Naringenin Nanoformulations for Neurodegenerative Diseases.Current pharmaceutical biotechnology · 2024Review
- Anti-neuroinflammatory effects of alkaloid-enriched extract fromPharmaceutical biology · 2023Article
- Redox-Mechanisms of Molecular Hydrogen Promote Healthful Longevity.Antioxidants (Basel, Switzerland) · 2023Review
- Long-Term Supplementation ofNutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Alzheimer's disease (AD) is a gradually growing irreversible illness of the brain that almost affects every fifth person (aged > 80 years) in the world. World Health Organization (WHO) also revealed that the prevalence of this disease will enhance (upto double) significantly upto 2030. The poor cholinergic transmission at the synapse is considered to be one of the main reasons behind the progression and occurrence of this disorder. Natural inhibitors of acetylcholine (ACh) such as galanthamine and rivastigmine are used commercially in the treatmentof AD. The biomolecules such assesquiterpenes, possess a great structural diversity and are responsible for a plethora of pharmacological properties. The potential of various sesquiterpenes as anticholinesterase has been reviewed in this article. For this purpose, the various databases, mainly PubMed, Scopus, and Web of Science were investigatedwith different keywords such as "sesquiterpenes+acetylcholinesterase" and "sesquiterpenes+cholinesterase+inhibitors" in the surveyed time frame (2010-2020). A vast literature was evident in the last decade, which affirms the potential of various sesquiterpenes in the improvement of cholinergic transmission by inhibiting the AChE. After data analysis, it was found that 12 compounds out of a total of 58 sesquiterpenes were reported to possess IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.